Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 6:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 4,260 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Blood samples collected Clear all
Completed No phase listed Observational Results available

Measurement of Relaxin Peptide in Multiple Sclerosis (MS)

NCT01909492
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Blood Draw, Lumbar Puncture
Procedure
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 22, 2025 · Synced Oct 14, 2026, 6:38 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Human Immunome Program

NCT03118687
View directory record Official record
Conditions
Healthy
Interventions
Biospecimen and survey collection
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 49 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 8, 2021 · Synced Oct 14, 2026, 6:38 PM EDT
Recruiting Phase 1 Interventional

TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer

NCT06868433
View directory record Official record
Conditions
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Nasopharyngeal Squamous Cell Carcinoma, Metastatic Oral Cavity Squamous Cell Carcinoma, Metastatic Oropharyngeal Squamous Cell Carcinoma, Metastatic Sinonasal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Nasopharyngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Recurrent Sinonasal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Unknown Primary, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Sinonasal Cancer AJCC v8
Interventions
Autologous Tumor Membrane Vesicles Vaccine, Biospecimen Collection, Computed Tomography, Echocardiography, Magnetic Resonance Imaging, Pembrolizumab, Positron Emission Tomography, Surgical Procedure
Biological · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 14, 2026, 6:38 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG

NCT00899847
View directory record Official record
Conditions
Transplantation, Homologous, Transplantation, Autologous, Multiple Myeloma, Blood and Marrow Transplant (BMT)
Interventions
Autologous peripheral blood stem cells (auto-PBSC) transplantation, Allogeneic peripheral blood stem cells (allo-PBSC) transplantation, Filgrastim, Cyclophosphamide, Melphalan, Cyclosporine, Total lymphoid irradiation, Rabbit anti-thymocyte globulin, Mycophenolate Mofetil 250mg, Solumedrol, Diphenhydramine, Acetaminophen, Hydrocortisone
Procedure · Drug · Radiation + 1 more
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2017 · Synced Oct 14, 2026, 6:38 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Platelet Rich Plasma for Patients With Recurrent Implantation Failure

NCT03379649
View directory record Official record
Conditions
Infertility
Interventions
Platelet rich plasma, Placebo
Combination Product
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Sunnyvale, California
Source: ClinicalTrials.gov public record
Updated Dec 22, 2023 · Synced Oct 14, 2026, 6:38 PM EDT
Terminated Phase 2 Interventional

Tipifarnib in Treating Patients With Anemia or Neutropenia and Large Granular Lymphocyte Leukemia

NCT00360776
View directory record Official record
Conditions
Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia, T-cell Large Granular Lymphocyte Leukemia
Interventions
tipifarnib, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Oct 14, 2026, 6:38 PM EDT
Completed No phase listed Observational

A Pilot Study of Influenza Viruses Isolated From Immunocompromised Children and Adolescents

NCT02352389
View directory record Official record
Conditions
Influenza, Human
Interventions
Blood sample, Nasal swab, Oropharyngeal swab, Stool sample, Symptom checklist
Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Oct 14, 2026, 6:38 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations

NCT00823654
View directory record Official record
Conditions
Breast Cancer
Interventions
Blood draw and questionnaires
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
609 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2027
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 14, 2026, 6:38 PM EDT
Recruiting Phase 1 Interventional

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

NCT06696768
View directory record Official record
Conditions
Metastatic Colorectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Unresectable Colorectal Adenocarcinoma
Interventions
Bevacizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Emavusertib, Fluorouracil, Leucovorin Calcium, Magnetic Resonance Imaging, Oxaliplatin, Positron Emission Tomography
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
13
States / cities
Gainesville, Florida • Shiloh, Illinois • Fairway, Kansas + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 14, 2026, 6:38 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Stem Cell Collection

NCT00316069
View directory record Official record
Conditions
Stem Cells
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
429 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 14, 2026, 6:38 PM EDT
Active, not recruiting Phase 2 Interventional

A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma

NCT04708418
View directory record Official record
Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Recurrent Cutaneous Melanoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Pembrolizumab, Positron Emission Tomography, Surgical Procedure, VLP-encapsulated TLR9 Agonist CMP-001
Procedure · Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
187
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Tucson, Arizona + 134 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 14, 2026, 6:38 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

AMPLIFI: Adaptive Modulation of Plasticity Through Lactate and Fitness Interventions

NCT06950060
View directory record Official record
Conditions
Stroke, Chronic, Aging, Cognitive Decline, Motor Dysfunction, Neuroplasticity
Interventions
High intensity cycling, Low-intensity cycling, Health education session, Moderate Intensity Aerobic Exercise
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 14, 2026, 6:38 PM EDT
Completed No phase listed Observational

Translation Evaluation of Aging, Inflammation and HIV in Lung Function (TEAL)

NCT02154880
View directory record Official record
Conditions
HIV, COPD, Pulmonary Disease, Aging
Interventions
PFT, lab work, 6MWT, questionnaires
Procedure · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 80 Years
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 14, 2026, 6:38 PM EDT
Not yet recruiting Phase 2 Interventional

Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome

NCT07819396
View directory record Official record
Conditions
Acute Biphenotypic Leukemia, Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Undifferentiated Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, Burkitt Leukemia, Burkitt Lymphoma, Chronic Myeloid Leukemia, BCR-ABL1 Positive, Lymphoblastic Lymphoma, Mast Cell Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome
Interventions
Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Cyclophosphamide, Fludarabine, Total-Body Irradiation
Biological · Procedure · Drug + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 14, 2026, 6:38 PM EDT
Terminated No phase listed Observational

Observational Analysis of T Cell Responses to SPIREs for Multiple Allergens in Subjects With Allergy in North America

NCT02601690
View directory record Official record
Conditions
Allergy
Interventions
Blood Sampling
Other
Lead sponsor
Adiga Life Sciences, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Upland, California • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Oct 14, 2026, 6:38 PM EDT
Terminated No phase listed Observational

Liver and Biliary Tumor Tissue Registry

NCT02917759
View directory record Official record
Conditions
Hepatocellular Carcinoma, Cholangiocarcinoma
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 14, 2026, 6:38 PM EDT
Completed Early Phase 1 Interventional Results available

Effects of Aminocaproic Acid (ACA) on Rosacea-specific Inflammation

NCT01398280
View directory record Official record
Conditions
Rosacea
Interventions
Topical aminocaproic acid (ACA) mixed with Vanicream, Vehicle cream
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 13, 2019 · Synced Oct 14, 2026, 6:38 PM EDT
Completed Phase 2 Interventional

A Follow-up Study to Assess Resistance to ABT-072 in HCV-infected Subjects Administered ABT-072 in Prior ABT-072 Studies

NCT00872196
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
ABT-072
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2013 · Synced Oct 14, 2026, 6:38 PM EDT
Recruiting No phase listed Observational

Mixed Methods Study of Health-Related Social Needs in African American Adults With Chronic Kidney Disease and Type 2 Diabetes Mellitus

NCT05692388
View directory record Official record
Conditions
Diabetic Nephropathy Type 2 - Uncontrolled, Diabetes Mellitus, Type 2, Chronic Kidney Diseases
Interventions
Patient and Community Stakeholder Interviews, Cross-sectional Study Participants, Focus Groups and Intervention Mapping
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 14, 2026, 6:38 PM EDT
Completed No phase listed Observational

Understanding the Molecular and Genetic Differences Between Germ Cell Tumor at the Time of the Initial Diagnosis and at Late Relapse

NCT02679950
View directory record Official record
Conditions
Neoplasms, Germ Cell and Embryonal
Interventions
Next generation genome sequencing
Genetic
Lead sponsor
Nasser Hanna
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Oct 14, 2026, 6:38 PM EDT
Completed No phase listed Observational

Blood and Saliva Sample Collection for AREDS 2

NCT01553474
View directory record Official record
Conditions
Age-Related Macular Degeneration, Eye Diseases
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
55 Years to 85 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Oct 14, 2026, 6:38 PM EDT
Completed Phase 2 Interventional Results available

The Effects of Patiromer on Serum Potassium Level and Gut Microbiome of ESRD Patients With Hyperkalemia

NCT03326583
View directory record Official record
Conditions
ESRD, Hyperkalemia, End Stage Renal Disease
Interventions
Patiromer
Drug
Lead sponsor
Dominic Raj
Other
Eligibility
18 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 14, 2026, 6:38 PM EDT
Recruiting Phase 1 Interventional

Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors

NCT06364410
View directory record Official record
Conditions
Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Gastric Carcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Unresectable Gastric Carcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Unresectable Malignant Solid Neoplasm
Interventions
Azenosertib, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Trastuzumab Deruxtecan
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 14, 2026, 6:38 PM EDT
Completed No phase listed Observational

Early Prediction of Major Adverse Cardiovascular Events Using Remote Monitoring

NCT03064360
View directory record Official record
Conditions
Ischemic Heart Disease
Interventions
Laboratory Biomarker Analysis, Patient Activity, Questionnaires
Other · Device · Behavioral
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 105 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Oct 14, 2026, 6:38 PM EDT